2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-163016
    RNA polymerase-IN-2 2447106-79-6 98%
    RNA polymerase-IN-2 (compound 5) is s DNA-dependent RNA polymerase inhibitor. RNA polymerase-IN-2 inhibits CYP isozymes.
    RNA polymerase-IN-2
  • HY-163029
    CTSL/B-IN-1 98%
    CTSLCTSB-IN-1 (compound 212-148) is a bispecific inhibitor of host viral spike cleaver proteins CTSL/CTSB and TMPRSS2 with IC50s of 2.13/64.07 nM and 1.38 μM, respectively. CTSLCTSB-IN-1 blocks two relevant SARS-CoV-2 viral entry pathways by inhibiting the viral spike cleavage and can be applied to anti-SARS-CoV-2 research.
    CTSL/B-IN-1
  • HY-163030
    LasB-IN-1 98%
    LasB-IN-1 (compound 5f) is a potent and orally active inhibitor of LasB (IC50 = 8.7 μM). LasB-IN-1 effectively attenuates elastase production and biofilm formation by P. aeruginosa while alleviating the inflammatory response through downregulating MAPK and NF-κB pathways. LasB-IN-1 is potential to be a novel anti-infective candidate against drug-resistant infections.
    LasB-IN-1
  • HY-163033
    Antitubercular agent-42 98%
    Antitubercular agent-42(19) is a selective fatty acyl-AMP ligase (FAAL) inhibitor (MIC90 = 1.4 µg/mL for M. tuberculosis H37Rv). Antitubercular agent-42 shows antitubercular activity.
    Antitubercular agent-42
  • HY-163063
    Antimalarial agent 34 98%
    Antimalarial agent 34 is a modest PfARK1/3 inhibitor and shows potent antiplasmodial activity (EC50 = 0.16 μM).
    Antimalarial agent 34
  • HY-163067
    SARS-CoV-2-IN-71 98%
    SARS-CoV-2-IN-71 (compound 8h) is a potent inhibitor of SARS-CoV-2. SARS-CoV-2-IN-71 inhibits coronavirus replication at multiple stages. SARS-CoV-2-IN-71 displays anti-coronaviral effect by simultaneously acting on 3CLpro and TMPRSS2.
    SARS-CoV-2-IN-71
  • HY-163069
    Antitubercular agent-43 98%
    Antitubercular agent-43 (compound A11) is an orally active and potent antitubercular agent. Antitubercular agent-43 shows highly metabolic stability against human and mouse cytochrome P450 enzymes. Antitubercular agent-43 exhibits bactericidal efficacy in acute TB infection mouse model.
    Antitubercular agent-43
  • HY-163070
    Antimalarial agent 35 98%
    Antimalarial agent 35 (compound QP11) is a selective inhibitor FP2. Antimalarial agent 35 has antimalarial activity and shows synergistic effects when combined with chloroquine(HY-17589A).
    Antimalarial agent 35
  • HY-163073
    Anti-MRSA agent 9 98%
    Anti-MRSA agent 9 (compound 39) shows antibacterial effects against clinically isolated methicillin-resistant Staphylococcus aureus (MRSA) with MIC values of 1 μg/ml. Anti-MRSA agent 9 also shows anti-MRSA efficacy in vivo.
    Anti-MRSA agent 9
  • HY-163088
    CHIKV-IN-4 1269363-88-3 98%
    CHIKV-IN-4 (compound 31b) is a potent and selective CHIKV inhibitor. CHIKV-IN-4 inhibits the Chikungunya virus with the EC50 value of 0.6 μM.
    CHIKV-IN-4
  • HY-163107
    Antimycobacterial agent-7 98%
    Antimycobacterial agent-7 (compound 4) is a 1,2,4-triazole anti-tuberculosis agent (MIC: 2 μg/mL). Antimycobacterial agent-7 inhibits Mtb KatG and causes the accumulation of ROS in Mtb cells. ROS produces oxidative damage, leading to the death of Mtb.
    Antimycobacterial agent-7
  • HY-163111
    Antibacterial agent 170 2764797-36-4 98%
    Antibacterial agent 170 (compound 6b) is a potent antibacterial agent which inhibits the formation of P. aeruginosa PAO1 biofilm. Antibacterial agent 170 exhibits quorum sensing inhibitor effect by the las system. Antibacterial agent 170 can used in study microbial resistance.
    Antibacterial agent 170
  • HY-163132
    DDABT1 2777045-35-7 98%
    DDABT1 has anti-CHIKV activity (IC50 of 14.53 μM) and the ability to reduce inflammation and arthritis.
    DDABT1
  • HY-163142
    Antibacterial agent 172 3023114-93-1 98%
    Antibacterial agent 172 (Compound 6a) is a <,i>Clostridioides difficile (Cd) SpoVD inhibitor (IC50=89 nM) that effectively inhibits sporulation of Clostridioides difficile. Antibacterial agent 172 can be used in the study of bacterial infections.
    Antibacterial agent 172
  • HY-163177
    HIV-1 inhibitor-63 98%
    HIV-1 inhibitor-63 (compound S17) is a potent HIV-1 inhibitor. HIV-1 inhibitor-63 inhibits integrase-Ku70 complex formation with an IC50 value of 12 µM. HIV-1 inhibitor-63 inhibits HIV-1 post-integration DNA repair.
    HIV-1 inhibitor-63
  • HY-163182
    CSNK2A-IN-2 98%
    CSNK2A-IN-2 (compound 6c) is a selective CSNK2A inhibitor with antiviral activity. CSNK2A-IN-2 exhibits an inhibitory effect on viral replication and is selective for PIM3.
    CSNK2A-IN-2
  • HY-163186
    SARS-CoV-2 Mpro-IN-13 98%
    SARS-CoV-2 Mpro-IN-13 (compound 20j) is a covalent SARS-CoV-2 Protease Mpro inhibitor with an IC50 value of 19.0 nM. SARS-CoV-2 Mpro-IN-13 processes antiviral activity with an EC50 value of 138.1 nM.
    SARS-CoV-2 Mpro-IN-13
  • HY-163191
    NDM-1 inhibitor-5 1613045-02-5 98%
    NDM-1 inhibitor-5 (compound 57) is a potent NDM-1 inhibitor, with a Ki of 2.5 μM. NDM-1 inhibitor-5 also shows antibacterial synergistic activity with meropenem (HY-13678).
    NDM-1 inhibitor-5
  • HY-163206
    SARS-CoV-2-IN-77 98%
    SARS-CoV-2-IN-77 (compound 11e) is a cathepsin L and cathepsin S inhibitor with Ki values of 111 nM and 103 nM, respectively. SARS-CoV-2-IN-77 inhibits SARS-CoV-2 with an EC50 value of 38.4 nM in Calu-3 cells without showing cytotoxicity.
    SARS-CoV-2-IN-77
  • HY-163211
    SARS-CoV-2 Mpro-IN-14 2679814-93-6 98%
    SARS-CoV-2 Mpro-IN-14 (Compound 19) is an inhibitor of SARS-CoV-2 Mpro with an IC50 of 0.044 μM. SARS-CoV-2 Mpro-IN-14 exhibits water solubility, has no cytotoxicity, and can be used in the study of COVID-19.
    SARS-CoV-2 Mpro-IN-14
Cat. No. Product Name / Synonyms Application Reactivity